secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001819790-25-000107
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q2 net product sales $102.7M, up 152% YoY; net loss narrows to $20.3M
----------------------------------------------------------------------------

- Record Q2 net product sales $102.7M (+152% YoY); 91,000 bottles distributed.
- Net loss $20.3M ($0.48 loss per share) vs $33.3M ($0.88) in Q2 2024.
- Gross-to-net discount ~45%; DTC campaign drove 400% web engagement and 30% more prescribers.
- Cash $381.1M; pipeline: Phase 2 TP-04 (ocular rosacea) H2 2025, TP-05 (Lyme) in 2026.
- Global expansion: Japan regulatory meetings H2 2025; EU approval expected 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979025000107/0001819790-25-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979025000107/tars-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001819790-25-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer